Anti-phosphatidylserine/prothrombin antibodies at two points: Correlation with lupus anticoagulant and thrombotic risk marker

dc.contributor.authorEgri, Natalia
dc.contributor.authorBentow, Chelsea
dc.contributor.authorRubio, Laura
dc.contributor.authorNorman, Gary L.
dc.contributor.authorLópez Sañudo, Susana
dc.contributor.authorMahler, Michael
dc.contributor.authorPérez Isidro, Albert
dc.contributor.authorCervera i Segura, Ricard, 1960-
dc.contributor.authorViñas, Odette
dc.contributor.authorEspinosa Garriga, Gerard
dc.contributor.authorRuiz Ortiz, Estíbaliz
dc.date.accessioned2023-03-16T13:21:30Z
dc.date.available2023-03-16T13:21:30Z
dc.date.issued2021-10-21
dc.date.updated2023-03-16T13:21:30Z
dc.description.abstractPatients with autoimmune diseases (ADs) are a challenge for the intensivist; it is hard to differentiate among infection, disease activity, and combinations of both, leading to high mortality. This study is a retrospective analysis of 124 critically ill patients admitted to the intensive care unit (ICU) in a university hospital between 2008 and 2016. Bivariate case-control analysis was performed, using patients who died as cases; later, analysis using a logistic regression model with variables that were associated with mortality was conducted. Four variables were consistently associated with mortality in the logistic regression model and had adequate prediction value (Hosmer and Lemeshow statistic = 0.760; Nagelkerke R-squared = 0.494). The risk of death was found to be statistically associated with the following: shock at admission to ICU [odds ratio (OR): 7.56; 95% confidence interval (CI): 1.78-31.97, p = 0.006], hemoglobin level <8 g/dL (OR: 16.12; 95% CI: 3.35-77.52, p = 0.001), use of cytostatic agents prior to admission to the ICU (OR: 8.71; 95% CI: 1.23-61.5, p = 0.03), and low levels ofcomplement C3 (OR: 5.23; 95% CI: 1.28-21.35, p = 0.02). These variables can guide clinicians in the early identification of patients with AD with increased risk of death during hospitalization, leading to initial therapies seeking to improve survival. These results should be evaluated prospectively in future studies to establish their predictive power.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec719931
dc.identifier.issn1664-3224
dc.identifier.pmid34790198
dc.identifier.urihttps://hdl.handle.net/2445/195378
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fimmu.2021.754469
dc.relation.ispartofFrontiers in Immunology, 2021, vol. 12, p. 754469
dc.relation.urihttps://doi.org/10.3389/fimmu.2021.754469
dc.rightscc-by (c) Egri, Natalia et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationFosfolípids
dc.subject.classificationLupus
dc.subject.classificationAnticoagulants (Medicina)
dc.subject.classificationTrombosi
dc.subject.classificationFactors de risc en les malalties
dc.subject.classificationObesitat mòrbida
dc.subject.classificationComplicacions en l'embaràs
dc.subject.otherPhospholipids
dc.subject.otherLupus
dc.subject.otherAnticoagulants (Medicine)
dc.subject.otherThrombosis
dc.subject.otherRisk factors in diseases
dc.subject.otherMorbid obesity
dc.subject.otherComplications of pregnancy
dc.titleAnti-phosphatidylserine/prothrombin antibodies at two points: Correlation with lupus anticoagulant and thrombotic risk marker
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
719931.pdf
Mida:
1.37 MB
Format:
Adobe Portable Document Format